Tilray® Announces Support Of Two New Clinical Research Studies In Australia And Canada

Tilray® Announces Support Of Two New Clinical Research Studies In Australia And Canada

Tilray cannabis products will be used to support the Murdoch Children’s Research Institute led pilot study to evaluate the feasibility and acceptability of a randomized placebo-controlled trial of the efficacy of cannabidiol (CBD) oral solution in reducing Severe Behavioral Problems in children with Intellectual Disabilities

 Tilray CBD and THC capsules will be used in a study examining the safety, tolerability and effectiveness of medical cannabis on immune activation in people living with HIV being conducted by the McGill University Health Centre.

Tilray® Expands Manufacturing Capacity With New Processing License From Health Canada

Tilray® Expands Manufacturing Capacity With New Processing License From Health Canada

Newly-acquired Natura Naturals Inc. located in Leamington, Ontario obtains processing license, allowing it to produce a wide range of cannabis form factors for the Canadian market.

NANAIMO, B.C. – Natura Naturals Inc. (“Natura”), a wholly-owned subsidiary of Tilray, Inc. (NASDAQ:TLRY) and High Park Holdings Ltd. (“High Park”), has received a standard processing license under the Cannabis Act. The Natura greenhouse facility, which previously held a standard cultivation license, will now be able to manufacture a wide range of cannabis form factors from cannabis starting material, including oil, pre-rolls, and novel formats such as topicals and edibles.

Tilray’s Christine St.Clare Named Among The Most Influential Corporate Directors In The U.S.

Tilray’s Christine St.Clare Named Among The Most Influential Corporate Directors In The U.S.

Annual NACD Directorship 100 List Recognizes the Most Influential Corporate Directors and Governance Experts.

The National Association of Corporate Directors (NACD) announced the 2019 NACD Directorship 100, a list of the most influential leaders in the boardroom and corporate governance community. Included among this year’s esteemed honorees is Christine St.Clare, a member of the Board of Directors and Audit Committee Chair for Tilray, a global pioneer in cannabis research, cultivation, production and distribution.

Tilray, Inc. Reports Full Year 2018 Financial Results

Revenue Rises 110.0% to $43.1 (C$56.4) Million in 2018
 
Strategic Partnerships and Acquisitions Position Tilray to Accelerate Global Sales Growth and Drive Long-Term Shareholder Value

 
NANAIMO, BRITISH COLUMBIA – Tilray, Inc., (“Tilray” or the “Company”) (Nasdaq: TLRY) a global leader in cannabis research, cultivation, production and distribution, today reported financial results for the fourth quarter and year ended December 31, 2018. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
 
“2018 was a very successful year for Tilray with many corporate milestones. Our team made significant progress on our long-term initiatives including increasing production capacity, expanding and strengthening strategic partnerships, and acquiring complementary businesses to accelerate our future growth and leadership position in medical and adult-use cannabis,” commented Brendan Kennedy, President and Chief Executive Officer of Tilray. “Looking ahead, we remain committed to pursuing global growth opportunities and will be disciplined in deploying capital, particularly in the United States and Europe, where we believe we have multiple paths for value creation.”
 

Former Goldman Sachs Managing Director Andrew Pucher joins Tilray to lead the company’s global corporate development activity, including M&A and corporate investments

Former Goldman Sachs Managing Director Andrew Pucher joins Tilray to lead the company’s global corporate development activity, including M&A and corporate investments

Former Goldman Sachs Managing Director Andrew Pucher joins Tilray to lead the company’s global corporate development activity, including M&A and corporate investments

NANAIMO, B.C. - Today, Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis production, research, cultivation and distribution, announces the expansion of its global senior leadership team with the appointment of Andrew Pucher as Chief Corporate Development Officer. In his new role, Andrew will lead Tilray’s corporate development function, including the team that is responsible for M&A and corporate investments. He will be based in Toronto, ON, and report to CEO Brendan Kennedy. 

Tilray® Announces Successful Medical Cannabis Harvest in Portugal and Provides Update on Rapidly Expanding European Operations

Tilray® Announces Successful Medical Cannabis Harvest in Portugal and Provides Update on Rapidly Expanding European Operations

NANAIMO, B.C. – Tilray, Inc. (“Tilray” or “the Company”) (NASDAQ:TLRY), a global leader in cannabis research, cultivation, production and distribution, today announced that its wholly-owned subsidiary Tilray Portugal Unipessoal Lda. (“Tilray Portugal”) has completed a successful harvest of medical cannabis at the Company’s European Union (EU) Campus in Portugal.